Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01620515 · ClinicalTrials.gov registry record · Phase 2

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Nymox Corporation.

Completed
Registry status
Phase 2
Development phase
141
Enrollment target
20
Study locations

NCT01620515: Completed Phase 2 study of Prostate Cancer, sponsored by Nymox Corporation.

NCT01620515 is a Phase 2 study of Prostate Cancer that has completed, run by Nymox Corporation. The registered enrollment target is 141 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01620515, a Phase 2 study of Prostate Cancer, has completed, sponsored by Nymox Corporation.

COMPLETED
Registry status
Phase 2
Development phase
141 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the safety and efficacy of a single injection of NX-1207 for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients currently undergoing active surveillance. Study participants currently on active surveillance will be randomized either to treatment with a single intraprostatic injection of NX-1207 (2.5 mg or 15 mg) followed by active surveillance or to no treatment (continued active surveillance). Blinded efficacy evaluation will be by a second post-treatment prostate biopsy.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG NX-1207 2.5 mg
  • DRUG NX-1207 15 mg

Study Locations (20)

California

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Atherton
  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - La Mesa
  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Long Beach
  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - San Diego

Colorado

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Denver
  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Englewood

Florida

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Aventura
  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Naples

Maryland

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Annapolis
  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Baltimore

New York

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Garden City
  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - New York

Arizona

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Tucson

Connecticut

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - New Britain

Indiana

  • For information concerning this clinical site, please contact Nymox at 800-936-9669. - Jeffersonville

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2012-02-21
Est. Completion 2015-10-21
Phase Phase 2

Sponsor

Nymox Corporation

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01620515

The ClinicalTrials.gov registry entry for NCT01620515 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Nymox Corporation, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which NX-1207 2.5 mg is the first listed.

NCT01620515 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT01620515 about?

NCT01620515 is a clinical study titled "Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer". This study is designed to evaluate the safety and efficacy of a single injection of NX-1207 for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients currently undergoing active surveillance. Study participants currently on active surveillance will be randomized eith...

What is the current status of trial NCT01620515?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2012-02-21. Estimated completion is 2015-10-21.

What conditions does trial NCT01620515 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01620515?

The interventions under investigation include: NX-1207 2.5 mg (DRUG), NX-1207 15 mg (DRUG).

Who is sponsoring clinical trial NCT01620515?

This trial is sponsored by Nymox Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01620515 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.